Aker still in a great position with an awesome balance sheet.
Good Afternoon and welcome to an analysis on GWPH. Looking at the chart we can see that GWPH broke through the support line on 2/22 and is now testing it as the current Major Resistance line. We have fallen to the Major Support line on 3/2 and bounced back up to touch the resistance line again. We almost looked as though we were going to break into the...
This is biotech "at its best". An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions. And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ... Luckily, I closed one trade with a win for this stock. Conclusion: Stay away from small biotech firms!
SRNE looks bullish. So far this has been climbing up my original projections, however, exceeding my highest highs as this stock continues to display an extension of wave 3. IF in fact this current cycle of waves is only a WAVE 3 (per Elliot Wave analysis and rules), then this may reach and exceed the $21.00 mark! So here are the targets if this count is...
Looking at past trends, we can see that a major fall in price a few months ago was a result of it breaking a mini support line. It has one now, does this hold or does something happen that can potentially see prices crash? I'm only very new to this, this probably has no correlation... amy corrections/advice would be appreciated.
RAD pharmaceuticals has been in a downtrend and indicated by the reversal in trend plus my analysis, shows a wedge form showing the bulls are ready to step in.
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder...
NASDAQ:MYL is breaking out of a wedge that it has been consolidating in for nearly four years. This wedge appears to be a retest of the breakout from resistance that occurred in 2013, which was followed by a large rally during the "biotech bubble". I expect the wedge breakout to take us back to the all-time highs, at a minimum, and potentially to...
VRX yesterday has reached the first TP around 24.3/24.5 according to what happened some years ago. I expect some resistence here. if such hurdle will be step over, I expect another resistence at 26/27. This because some investors will take profit from the rally began in November: From 11 dollars to 19 (the neckline) 8 dollars of difference. 8+19= 27. Third TP...
Acadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it...
Despite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and...
Yesterday I bet on a new trend line but I had needed a confirmation about the minimum which was given today, this is why I decided to post my idea. If confirmed during next sessions the new uptrend will accelerate.
Apologies for the chart but I don't have the premium version. I tried to figure out the next levels: Here the summary: 1. 25.80 2. 33.20 3. 38.50
VRX after the correction largly expected, yesterday as demostrated a strong bullish counterattack closing the session slightly less than the short entry recovering mostly 100%. The pattern therefore shows clearly the uptrend line in place. Investors are considering a Q4 better than Q3 looking for new confirmation about debit reduction, so I expect price will move...
We reached 17.70 dollars and than a fast pullback as it was for the day before. Important resistence near 18 with possible retracement on the ascendent trendline first and the second dotted trendline after. Personally I sold it at 17 in order to see what it will look like next weeks. RSI overbought, MACD still positive.
We have seen in the last few days a dynamic resistance that characterized the pull back of the price from a threshold range between 16.95-16.75. Today the lowest minimum price touched 16.00 dollars (around -2% compare to opening). Violent and prompt reaction with high volatility intraday had set the price at 16.45 +0.3%. 16$ was the point where the ascendant trend...
DMPI has broken resistance on positive interim results of its clinical cancer drug, VAL-083. Analyst have a price target of $12. Bullish price action on trend analysis, chart patterns, and shorts covering.